New antibiotic candidate JKN2501 begins first human safety tests
NCT ID NCT07207291
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 30 times
Summary
This early-stage study tests whether a new drug called JKN2501 is safe in healthy adults and how the body processes it. About 66 healthy volunteers aged 18-45 will receive either the drug or a placebo by IV. The goal is to gather safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third hospital of Changsha
RECRUITINGChangsha, Hunan, 410035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.